fbpx Skip to main content

MONDAY, Nov. 30, 2020 (HealthDay News) — The incidence of and mortality rates for breast and colorectal cancers do not differ for individuals with and without multiple sclerosis (MS), while bladder cancer incidence and mortality rates are higher for MS patients, according to a study published online Nov. 25 in Neurology.

Ruth Ann Marrie, M.D., Ph.D., from the University of Manitoba in Winnipeg, Canada, and colleagues compared incidence rates and cancer-specific mortality rates in MS cases and matched controls selected based on birth year, sex, and region.

Data were included for 53,984 MS cases and 266,920 controls. The researchers observed no between-group difference in breast cancer risk (pooled hazard ratio, 0.92; 95 percent confidence interval, 0.78 to 1.09) or colorectal cancer risk (pooled hazard ratio, 0.83; 95 percent confidence interval, 0.64 to 1.07). There was also no between-group difference seen in mortality rates for breast and colorectal cancer. Among the MS cohort, bladder cancer incidence and mortality rates were higher. There were differences noted in the incidence of prostate, uterine, and central nervous system cancers between the MS and matched cohorts, but the rates of mortality were not different.

“This is good news for people with MS, because earlier studies have shown a link between MS and breast and colorectal cancers,” Marrie said in a statement. “While we did not find that link, our study did show that people with MS had a 72 percent greater risk of developing bladder cancer.”

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this article
You May Also Like::  Can Biosimilars help in implementing a value-based care approach in hematology-oncology?